imatinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 1423 152459-95-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • imatinib
  • gleevec
  • imatinib mesylate
  • imatinib mesilate
  • CGP-57-148B
  • CGP57148B
  • CGP-57148
  • CGP57148
  • STI-571
  • STI571
A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.
  • Molecular weight: 493.62
  • Formula: C29H31N7O
  • CLOGP: 4.38
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 2
  • TPSA: 86.28
  • ALOGS: -4.53
  • ROTB: 7
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 1 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 5 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 20.26 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 98 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 3.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.05 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 22 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 7, 2001 EMA Novartis Europharm Limited
May 10, 2001 FDA NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 1694.46 12.88 1643 38106 323736 50241639
Blast crisis in myelogenous leukaemia 662.47 12.88 137 39612 375 50565000
Drug resistance 610.35 12.88 298 39451 18691 50546684
Cytogenetic analysis abnormal 535.42 12.88 123 39626 623 50564752
Malignant neoplasm progression 439.59 12.88 390 39359 67734 50497641
Second primary malignancy 410.89 12.88 167 39582 6747 50558628
Periorbital oedema 318.30 12.88 127 39622 4885 50560490
Gene mutation identification test positive 262.18 12.88 50 39699 74 50565301
Philadelphia chromosome positive 253.41 12.88 59 39690 320 50565055
Chronic myeloid leukaemia recurrent 223.61 12.88 48 39701 166 50565209
Neoplasm malignant 220.40 12.88 168 39581 23547 50541828
Pleural effusion 193.48 12.88 277 39472 81177 50484198
Muscle spasms 192.75 12.88 350 39399 125203 50440172
Chromosome analysis abnormal 177.89 12.88 37 39712 105 50565270
Oedema 173.05 12.88 243 39506 69938 50495437
Leukaemia recurrent 171.29 12.88 56 39693 1198 50564177
Acute lymphocytic leukaemia recurrent 168.26 12.88 62 39687 1913 50563462
Chronic myeloid leukaemia transformation 162.70 12.88 33 39716 79 50565296
Eyelid oedema 144.44 12.88 91 39658 9375 50556000
Gastric antral vascular ectasia 142.01 12.88 40 39709 504 50564871
Eye swelling 141.12 12.88 121 39628 20023 50545352
Rheumatoid arthritis 124.53 12.88 9 39740 202541 50362834
Nausea 118.84 12.88 951 38798 704447 49860928
Bone marrow failure 117.48 12.88 126 39623 27498 50537877
Fluid retention 114.00 12.88 168 39581 50481 50514894
Haematotoxicity 110.79 12.88 72 39677 7823 50557552
Pancytopenia 106.37 12.88 216 39533 83814 50481561
Arthropathy 103.15 12.88 5 39744 157901 50407474
Anaemia 101.81 12.88 430 39319 252026 50313349
Face oedema 100.92 12.88 95 39654 17744 50547631
Product substitution issue 99.60 12.88 85 39664 13972 50551403
Chronic myeloid leukaemia 97.80 12.88 43 39706 2113 50563262
Conjunctival haemorrhage 95.40 12.88 47 39702 2997 50562378
Oedema peripheral 92.01 12.88 303 39446 157658 50407717
Drug hypersensitivity 88.98 12.88 43 39706 250967 50314408
Systemic lupus erythematosus 84.28 12.88 7 39742 140615 50424760
Normal newborn 84.16 12.88 57 39692 6634 50558741
Disease progression 81.94 12.88 211 39538 95655 50469720
Completed suicide 80.62 12.88 6 39743 131883 50433492
Gene mutation 79.97 12.88 32 39717 1239 50564136
Pseudoporphyria 79.86 12.88 20 39729 154 50565221
Cytogenetic abnormality 79.79 12.88 25 39724 464 50564911
Blast cell crisis 77.86 12.88 17 39732 65 50565310
Generalised oedema 77.43 12.88 73 39676 13658 50551717
Metastases to liver 77.32 12.88 87 39662 20017 50545358
Thrombocytosis 76.14 12.88 48 39701 4948 50560427
Pain 74.95 12.88 221 39528 578682 49986693
Swelling face 74.76 12.88 142 39607 52453 50512922
Recurrent cancer 73.15 12.88 33 39716 1724 50563651
Thrombocytopenia 72.61 12.88 243 39506 127430 50437945
Growth retardation 70.82 12.88 28 39721 1050 50564325
Vomiting 69.05 12.88 606 39143 460152 50105223
Therapeutic product effect decreased 68.74 12.88 12 39737 136038 50429337
Splenomegaly 65.56 12.88 57 39692 9603 50555772
Pericardial effusion 63.59 12.88 89 39660 25500 50539875
Chronic graft versus host disease 63.29 12.88 35 39714 2832 50562543
Gastrointestinal stromal tumour 60.52 12.88 24 39725 907 50564468
Hepatotoxicity 59.35 12.88 89 39660 27137 50538238
Bone pain 59.24 12.88 121 39628 47108 50518267
Glossodynia 58.80 12.88 10 39739 115559 50449816
Off label use 58.54 12.88 185 39564 474241 50091134
Rash 58.21 12.88 561 39188 436910 50128465
Therapeutic response decreased 58.05 12.88 120 39629 47111 50518264
Exposure via father 57.87 12.88 17 39732 251 50565124
Diarrhoea 57.75 12.88 710 39039 587766 49977609
Hypotension 55.38 12.88 62 39687 235407 50329968
Neoplasm recurrence 55.28 12.88 30 39719 2339 50563036
Leukaemia 54.28 12.88 34 39715 3465 50561910
Graft versus host disease 53.58 12.88 42 39707 6124 50559251
Neoplasm progression 53.41 12.88 88 39661 29069 50536306
Polymerase chain reaction positive 52.52 12.88 12 39737 59 50565316
Haemoglobin decreased 52.16 12.88 218 39531 126998 50438377
White blood cell count increased 51.54 12.88 107 39642 42133 50523242
Lower respiratory tract infection 51.26 12.88 7 39742 95194 50470181
Joint swelling 50.98 12.88 71 39678 245215 50320160
Sinusitis 50.78 12.88 36 39713 170522 50394853
Therapy non-responder 50.67 12.88 119 39630 50903 50514472
Confusional state 50.60 12.88 43 39706 185885 50379490
Wound 49.92 12.88 11 39738 105783 50459592
Product use issue 49.37 12.88 28 39721 149447 50415928
Eye haemorrhage 49.21 12.88 43 39706 7292 50558083
Neutropenia 49 12.88 238 39511 147727 50417648
Exposure via body fluid 48.87 12.88 17 39732 442 50564933
Discomfort 47.77 12.88 13 39736 108367 50457008
Metastases to peritoneum 47.69 12.88 29 39720 2804 50562571
Fall 47.58 12.88 122 39627 334810 50230565
Cardiac output decreased 47.56 12.88 20 39729 880 50564495
Leukocytosis 46.65 12.88 72 39677 22507 50542868
Condition aggravated 46.32 12.88 103 39646 296955 50268420
Drug intolerance 45.97 12.88 312 39437 218792 50346583
Eye oedema 45.89 12.88 22 39727 1321 50564054
Myalgia 45.58 12.88 206 39543 124113 50441262
Platelet count increased 44.48 12.88 56 39693 14484 50550891
Platelet count decreased 41.58 12.88 173 39576 100553 50464822
Jaundice 40.85 12.88 74 39675 26355 50539020
Blast cells present 40.03 12.88 14 39735 370 50565005
Myelofibrosis 39.83 12.88 19 39730 1128 50564247
Overdose 38.59 12.88 15 39734 99712 50465663
Erythrocyanosis 36.90 12.88 6 39743 0 50565375
Tumour excision 36.46 12.88 13 39736 364 50565011
Urinary tract infection 36.28 12.88 76 39673 223944 50341431
Periorbital swelling 36.26 12.88 21 39728 1856 50563519
Blast cell count increased 35.84 12.88 13 39736 383 50564992
Oncologic complication 35.80 12.88 10 39739 122 50565253
Skin fragility 35.46 12.88 14 39735 523 50564852
Peripheral arterial occlusive disease 34.93 12.88 26 39723 3511 50561864
Therapeutic response delayed 34.86 12.88 14 39735 547 50564828
Musculoskeletal stiffness 34.59 12.88 30 39719 128451 50436924
Blood lactate dehydrogenase increased 34.43 12.88 58 39691 19504 50545871
Nasopharyngitis 34.23 12.88 62 39687 192865 50372510
Pneumatosis intestinalis 34.05 12.88 21 39728 2082 50563293
Ascites 33.82 12.88 82 39667 35779 50529596
Bone marrow oedema 32.97 12.88 15 39734 799 50564576
Psoriasis 32.90 12.88 7 39742 68993 50496382
Bone marrow transplant 32.79 12.88 14 39735 640 50564735
Acute graft versus host disease 32.34 12.88 26 39723 3932 50561443
Toxic skin eruption 32.32 12.88 42 39707 11209 50554166
Breast cancer 32.17 12.88 90 39659 42800 50522575
White blood cell count decreased 31.87 12.88 178 39571 116544 50448831
Pericarditis 31.85 12.88 11 39738 78678 50486697
Loss of personal independence in daily activities 31.62 12.88 8 39741 70042 50495333
Chloroma 31.17 12.88 10 39739 201 50565174
Pulse waveform abnormal 30.84 12.88 8 39741 72 50565303
Trisomy 8 30.75 12.88 5 39744 0 50565375
Ankle brachial index decreased 30.74 12.88 8 39741 73 50565302
Jaw operation 30.42 12.88 14 39735 766 50564609
Carotid intima-media thickness increased 30.36 12.88 8 39741 77 50565298
Hypersensitivity 30.03 12.88 79 39670 215082 50350293
Cardiotoxicity 29.77 12.88 32 39717 6995 50558380
Right ventricular failure 29.15 12.88 48 39701 15845 50549530
Tumour haemorrhage 28.43 12.88 16 39733 1339 50564036
Surgery 28.41 12.88 69 39680 30136 50535239
Tumour necrosis 28.08 12.88 13 39736 721 50564654
Leukopenia 27.86 12.88 116 39633 67412 50497963
Asthma 27.72 12.88 18 39731 89319 50476056
Intentional product use issue 27.47 12.88 13 39736 76905 50488470
Exposure via partner 27.18 12.88 8 39741 119 50565256
Aplasia 26.89 12.88 23 39726 3790 50561585
Left ventricular dysfunction 26.78 12.88 37 39712 10469 50554906
Gastrointestinal toxicity 26.62 12.88 25 39724 4652 50560723
Intentional overdose 26.60 12.88 8 39741 62496 50502879
Typhoid fever 26.52 12.88 6 39743 28 50565347
Psoriatic arthropathy 26.43 12.88 3 39746 47029 50518346
Abortion spontaneous 25.95 12.88 82 39667 41690 50523685
Pubertal failure 24.64 12.88 5 39744 12 50565363
Slit-lamp tests abnormal 24.60 12.88 4 39745 0 50565375
Pyrexia 24.52 12.88 427 39322 379776 50185599
Transdifferentiation of neoplasm 24.36 12.88 5 39744 13 50565362
Blood pressure increased 24.31 12.88 42 39707 133090 50432285
Abortion 24.14 12.88 17 39732 2107 50563268
Cytopenia 24.03 12.88 32 39717 8743 50556632
Helicobacter infection 23.78 12.88 5 39744 49697 50515678
Urine odour abnormal 23.70 12.88 25 39724 5348 50560027
Arthritis 23.64 12.88 20 39729 86701 50478674
Liver disorder 23.06 12.88 73 39676 37149 50528226
Therapy partial responder 22.78 12.88 27 39722 6564 50558811
Papilloedema 22.58 12.88 20 39729 3453 50561922
Hepatic necrosis 22.41 12.88 24 39725 5224 50560151
Peritoneal lesion 22.36 12.88 4 39745 3 50565372
Mobility decreased 22.33 12.88 18 39731 79930 50485445
Back pain 22.28 12.88 93 39656 219937 50345438
Syncope 22.19 12.88 29 39720 102973 50462402
Dizziness 21.79 12.88 171 39578 346198 50219177
Inappropriate schedule of product administration 21.57 12.88 15 39734 71816 50493559
Chylothorax 21.49 12.88 8 39741 254 50565121
Injury 21.30 12.88 6 39743 48919 50516456
Acute lymphocytic leukaemia 21.08 12.88 16 39733 2225 50563150
Basophilia 20.94 12.88 4 39745 6 50565369
Agitation 20.69 12.88 8 39741 53376 50511999
Lacrimation increased 20.67 12.88 43 39706 16949 50548426
Anxiety 20.61 12.88 71 39678 177535 50387840
Fibromyalgia 20.56 12.88 5 39744 44973 50520402
Stem cell transplant 20.48 12.88 14 39735 1654 50563721
Disseminated intravascular coagulation 20.42 12.88 43 39706 17092 50548283
Suicidal ideation 20.34 12.88 9 39740 55376 50509999
Hepatic enzyme increased 20.27 12.88 49 39700 137331 50428044
Intracardiac mass 20.26 12.88 5 39744 36 50565339
Oral pigmentation 20.21 12.88 4 39745 8 50565367
Computerised tomogram abnormal 20.19 12.88 15 39734 2019 50563356
Flushing 20.12 12.88 14 39735 67001 50498374
Urticaria 20.09 12.88 45 39704 129516 50435859
Somnolence 20.05 12.88 59 39690 154926 50410449
Neoplasm 20.02 12.88 24 39725 5904 50559471
Therapy interrupted 19.99 12.88 47 39702 20105 50545270
Hallucination 19.80 12.88 6 39743 46651 50518724
Drug ineffective 19.73 12.88 492 39257 818841 49746534
Myelocytosis 19.60 12.88 4 39745 10 50565365
Insomnia 19.56 12.88 71 39678 174794 50390581
Anaphylactic reaction 19.51 12.88 9 39740 54046 50511329
Tremor 19.42 12.88 38 39711 114865 50450510
Blood test abnormal 19.18 12.88 33 39716 11286 50554089
Obliterative bronchiolitis 19.15 12.88 14 39735 1839 50563536
Impaired healing 19.13 12.88 16 39733 69770 50495605
Exophthalmos 19.02 12.88 12 39737 1238 50564137
Exposure during pregnancy 18.95 12.88 161 39588 120854 50444521
Therapy cessation 18.93 12.88 54 39695 25957 50539418
Hepatic failure 18.81 12.88 62 39687 32221 50533154
Hyponatraemia 18.79 12.88 29 39720 96110 50469265
Aspiration pleural cavity 18.72 12.88 10 39739 755 50564620
Hypertension 18.56 12.88 94 39655 211109 50354266
Knee arthroplasty 18.45 12.88 3 39746 35843 50529532
Product dose omission issue 18.42 12.88 78 39671 183760 50381615
Fibrin degradation products increased 18.28 12.88 6 39743 130 50565245
Abortion induced 18.19 12.88 29 39720 9315 50556060
Acute kidney injury 18.12 12.88 105 39644 227953 50337422
Eosinophilia 17.96 12.88 43 39706 18609 50546766
Acquired gene mutation 17.95 12.88 10 39739 821 50564554
Gastrointestinal angiectasia 17.90 12.88 5 39744 61 50565314
Dengue fever 17.81 12.88 9 39740 606 50564769
Pigmentation disorder 17.47 12.88 18 39731 3746 50561629
Scleroderma-like reaction 17.47 12.88 5 39744 67 50565308
Type 2 diabetes mellitus 17.42 12.88 3 39746 34372 50531003
Microangiopathy 17.38 12.88 10 39739 873 50564502
Influenza like illness 17.25 12.88 12 39737 57447 50507928
Ejection fraction decreased 17.09 12.88 42 39707 18478 50546897
Morphoea 17.00 12.88 7 39742 292 50565083
Metastasis 16.93 12.88 19 39730 4356 50561019
Chronic graft versus host disease in skin 16.91 12.88 9 39740 675 50564700
Skin toxicity 16.89 12.88 18 39731 3895 50561480
Aspartate aminotransferase increased 16.87 12.88 112 39637 77886 50487489
Folliculitis 16.73 12.88 5 39744 39220 50526155
Abdominal discomfort 16.66 12.88 110 39639 231531 50333844
Irritable bowel syndrome 16.45 12.88 10 39739 51431 50513944
Blood bilirubin increased 16.45 12.88 59 39690 31979 50533396
Cardiac failure 16.33 12.88 109 39640 75931 50489444
Cellulitis 16.22 12.88 19 39730 70779 50494596
Lichen planus 16.17 12.88 13 39736 1966 50563409
Arthralgia 16.15 12.88 245 39504 438457 50126918
Dry skin 16.12 12.88 72 39677 43119 50522256
Blood blister 15.94 12.88 12 39737 1648 50563727
Desmoid tumour 15.90 12.88 5 39744 94 50565281
Tumour lysis syndrome 15.80 12.88 24 39725 7397 50557978
Lichenoid keratosis 15.63 12.88 11 39738 1361 50564014
Ocular hyperaemia 15.62 12.88 43 39706 20249 50545126
Acute myeloid leukaemia recurrent 15.50 12.88 11 39738 1379 50563996
Headache 15.37 12.88 293 39456 506242 50059133
Philadelphia positive chronic myeloid leukaemia 15.32 12.88 4 39745 37 50565338
Myeloid maturation arrest 15.16 12.88 3 39746 6 50565369
Osteoarthritis 15.10 12.88 19 39730 68587 50496788
Central nervous system leukaemia 14.91 12.88 5 39744 116 50565259
Subdural haematoma evacuation 14.84 12.88 3 39746 7 50565368
Hepatic mass 14.81 12.88 11 39738 1481 50563894
Loss of consciousness 14.78 12.88 38 39711 104315 50461060
Hyperhidrosis 14.74 12.88 30 39719 89396 50475979
Swelling of eyelid 14.73 12.88 12 39737 1848 50563527
Adverse event 14.72 12.88 8 39741 43755 50521620
Hyperkalaemia 14.49 12.88 10 39739 48079 50517296
Food interaction 14.46 12.88 8 39741 648 50564727
Delirium 14.35 12.88 6 39743 38186 50527189
Hepatomegaly 13.94 12.88 28 39721 10765 50554610
Red blood cell count decreased 13.85 12.88 58 39691 33777 50531598
Polyhydramnios 13.84 12.88 12 39737 2013 50563362
Cystitis 13.79 12.88 9 39740 44555 50520820
Primary adrenal insufficiency 13.75 12.88 4 39745 57 50565318
Blood alkaline phosphatase increased 13.59 12.88 62 39687 37464 50527911
Adenocarcinoma gastric 13.56 12.88 7 39742 493 50564882
Bone metabolism disorder 13.53 12.88 6 39743 301 50565074
Deep vein thrombosis 13.49 12.88 23 39726 73281 50492094
Complications of transplant surgery 13.36 12.88 5 39744 161 50565214
Irritability 13.31 12.88 3 39746 28423 50536952
Hepatic neoplasm 13.30 12.88 11 39738 1731 50563644
Gastrectomy 13.27 12.88 7 39742 515 50564860
Leukaemic infiltration extramedullary 13.26 12.88 4 39745 65 50565310
Gastric cancer 13.24 12.88 14 39735 3004 50562371
Balance disorder 13.12 12.88 22 39727 70568 50494807
Growth failure 13.11 12.88 6 39743 324 50565051
Acute leukaemia 13.11 12.88 9 39740 1071 50564304
Blood creatine phosphokinase increased 13.07 12.88 48 39701 26319 50539056
Aspergillus infection 13.05 12.88 21 39728 6800 50558575
Abdominal distension 13.04 12.88 100 39649 72803 50492572
Oxygen saturation 13.03 12.88 5 39744 173 50565202
Skull fractured base 12.98 12.88 4 39745 70 50565305
Pulmonary embolism 12.94 12.88 39 39710 101665 50463710
Therapy responder 12.94 12.88 6 39743 334 50565041

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 2489.57 11.76 2728 39947 339356 29192496
Drug resistance 850.85 11.76 474 42201 21066 29510786
Blast crisis in myelogenous leukaemia 738.45 11.76 169 42506 380 29531472
Second primary malignancy 586.39 11.76 254 42421 6451 29525401
Malignant neoplasm progression 483.10 11.76 563 42112 73296 29458556
Cytogenetic analysis abnormal 439.33 11.76 112 42563 458 29531394
Neoplasm malignant 372.93 11.76 257 42418 16668 29515184
Philadelphia chromosome positive 297.14 11.76 73 42602 247 29531605
Pleural effusion 224.49 11.76 385 42290 71523 29460329
Acute lymphocytic leukaemia recurrent 212.34 11.76 93 42582 2423 29529429
Drug intolerance 212.24 11.76 303 42372 48076 29483776
Gene mutation 192.81 11.76 68 42607 973 29530879
Chromosome analysis abnormal 187.12 11.76 43 42632 99 29531753
Periorbital oedema 161.57 11.76 84 42591 3231 29528621
Leukaemia recurrent 155.92 11.76 64 42611 1413 29530439
Chronic myeloid leukaemia transformation 152.49 11.76 37 42638 117 29531735
Metastases to liver 150.90 11.76 130 42545 11726 29520126
Chronic myeloid leukaemia recurrent 142.41 11.76 36 42639 141 29531711
Gene mutation identification test positive 137.81 11.76 33 42642 97 29531755
Oedema 117.39 11.76 210 42465 40273 29491579
Recurrent cancer 114.59 11.76 48 42627 1117 29530735
Therapeutic response decreased 111.55 11.76 157 42518 24554 29507298
White blood cell count increased 100.40 11.76 188 42487 37328 29494524
Blast cell crisis 99.61 11.76 24 42651 73 29531779
Drug abuse 97.97 11.76 4 42671 79879 29451973
Eyelid oedema 96.42 11.76 68 42607 4568 29527284
Gastrointestinal stromal tumour 93.37 11.76 37 42638 743 29531109
Muscle spasms 92.94 11.76 254 42421 64828 29467024
Completed suicide 89.77 11.76 12 42663 90234 29441618
Neoplasm progression 86.60 11.76 120 42555 18492 29513360
Chronic graft versus host disease 85.90 11.76 60 42615 3969 29527883
Neoplasm recurrence 84.77 11.76 46 42629 1931 29529921
Hypotension 81.93 11.76 96 42579 194258 29337594
Blast cells present 79.36 11.76 29 42646 462 29531390
Overdose 78.47 11.76 11 42664 79808 29452044
Polymerase chain reaction positive 77.95 11.76 21 42654 111 29531741
Gastric antral vascular ectasia 75.65 11.76 25 42650 290 29531562
Acute kidney injury 74.51 11.76 171 42504 265096 29266756
Therapy non-responder 73.04 11.76 147 42528 30764 29501088
Face oedema 71.37 11.76 81 42594 10202 29521650
Splenomegaly 70.00 11.76 91 42584 13188 29518664
Necrotising panniculitis 66.06 11.76 15 42660 32 29531820
Off label use 63.06 11.76 223 42452 300577 29231275
Fluid retention 61.68 11.76 117 42558 23443 29508409
Product substitution issue 59.87 11.76 70 42605 9102 29522750
Clonal evolution 59.55 11.76 17 42658 115 29531737
Fall 58.39 11.76 104 42571 177074 29354778
Bradycardia 57.99 11.76 12 42663 65617 29466235
Scleroderma 57 11.76 31 42644 1307 29530545
Blast cell count increased 56.57 11.76 28 42647 969 29530883
Prostate cancer 56.29 11.76 118 42557 25409 29506443
Acquired gene mutation 55.97 11.76 30 42645 1228 29530624
Metastases to peritoneum 55.97 11.76 32 42643 1488 29530364
Oncologic complication 55.74 11.76 19 42656 244 29531608
Central nervous system leukaemia 55.60 11.76 19 42656 246 29531606
Graft versus host disease 53.92 11.76 68 42607 9560 29522292
Chronic myeloid leukaemia 52.85 11.76 34 42641 1960 29529892
Disease progression 52.70 11.76 246 42429 81670 29450182
Thrombocytopenia 52.16 11.76 353 42322 134470 29397382
Myelofibrosis 51.76 11.76 30 42645 1432 29530420
Confusional state 49.81 11.76 67 42608 127810 29404042
Cytogenetic abnormality 49.45 11.76 24 42651 795 29531057
Treatment failure 47.62 11.76 139 42536 36800 29495052
Bone pain 47.51 11.76 91 42584 18361 29513491
Bone marrow necrosis 46.46 11.76 14 42661 117 29531735
Accident 46.02 11.76 40 42635 3648 29528204
Desmoid tumour 45.79 11.76 13 42662 86 29531766
Bone marrow failure 45.14 11.76 113 42562 27336 29504516
Typhoid fever 44.14 11.76 10 42665 21 29531831
Central nervous system neoplasm 43.27 11.76 12 42663 72 29531780
Toxicity to various agents 43.17 11.76 119 42556 173542 29358310
Exposure via father 43.00 11.76 13 42662 110 29531742
Endocarditis noninfective 42.49 11.76 13 42662 115 29531737
Pituitary apoplexy 42.12 11.76 10 42665 28 29531824
Hyperkalaemia 41.96 11.76 18 42657 61374 29470478
Haemoglobin decreased 41.43 11.76 283 42392 108092 29423760
Pulmonary embolism 41.42 11.76 30 42645 76504 29455348
Intentional overdose 41.10 11.76 4 42671 38524 29493328
Loss of therapeutic response 40.90 11.76 16 42659 310 29531542
Platelet count decreased 39.81 11.76 273 42402 104399 29427453
Tumour haemorrhage 39.46 11.76 31 42644 2454 29529398
Ascites 39.05 11.76 129 42546 36490 29495362
Somnolence 38.88 11.76 47 42628 93908 29437944
Surgery 37.88 11.76 64 42611 11715 29520137
Nausea 36.64 11.76 603 42072 288652 29243200
Tumour rupture 35.93 11.76 13 42662 201 29531651
Hallucination 35.91 11.76 10 42665 44702 29487150
Colon cancer 35.06 11.76 49 42626 7606 29524246
Tuberculosis 34.37 11.76 47 42628 7149 29524703
Tumour necrosis 34.18 11.76 21 42654 1116 29530736
Generalised oedema 33.72 11.76 59 42616 11106 29520746
Drug hypersensitivity 33.03 11.76 30 42645 68376 29463476
Gastrectomy 32.65 11.76 11 42664 136 29531716
Syncope 32.30 11.76 42 42633 81329 29450523
Seizure 32.14 11.76 53 42622 93070 29438782
Inappropriate schedule of product administration 32.08 11.76 12 42663 44460 29487392
Pneumonia 31.91 11.76 302 42373 319870 29211982
Eye swelling 31.86 11.76 50 42625 8607 29523245
Delirium 31.29 11.76 9 42666 39388 29492464
Pemphigus 31.16 11.76 20 42655 1148 29530704
Pulmonary aplasia 30.83 11.76 6 42669 3 29531849
Gastric cancer 30.31 11.76 36 42639 4758 29527094
Rhabdomyolysis 30.16 11.76 26 42649 60782 29471070
Malaria 29.61 11.76 11 42664 184 29531668
Dizziness 29.61 11.76 157 42518 189527 29342325
Growth retardation 29.47 11.76 22 42653 1614 29530238
Pericardial effusion 29.46 11.76 82 42593 21126 29510726
Oral pigmentation 29.11 11.76 6 42669 6 29531846
Rash 29.10 11.76 409 42266 189410 29342442
Tumour excision 29.08 11.76 10 42665 132 29531720
Oedema peripheral 28.73 11.76 251 42424 103306 29428546
Flushing 28.46 11.76 4 42671 28988 29502864
Blindness 28.17 11.76 57 42618 11966 29519886
Therapy partial responder 27.97 11.76 36 42639 5163 29526689
Deep vein thrombosis 27.92 11.76 25 42650 57374 29474478
Optic neuritis 27.77 11.76 28 42647 3081 29528771
Stem cell transplant 27.76 11.76 23 42652 1964 29529888
Renal tuberculosis 27.71 11.76 5 42670 0 29531852
Demyelination 27.63 11.76 26 42649 2628 29529224
Loss of CAR T-cell persistence 27.57 11.76 7 42668 28 29531824
Cardiac arrest 27.46 11.76 51 42624 85540 29446312
Metabolic acidosis 27.44 11.76 10 42665 37652 29494200
Anxiety 27.27 11.76 51 42624 85314 29446538
Tremor 27.14 11.76 40 42635 73498 29458354
Graft versus host disease in eye 27.08 11.76 11 42664 236 29531616
Blood lactate dehydrogenase increased 26.41 11.76 74 42601 19135 29512717
Skin hypopigmentation 26.26 11.76 11 42664 256 29531596
Drug interaction 26.22 11.76 172 42503 197213 29334639
Hyperhidrosis 25.94 11.76 33 42642 64507 29467345
Chloroma 25.66 11.76 13 42662 473 29531379
Blood pressure increased 25.47 11.76 42 42633 73761 29458091
Metamyelocyte count increased 25.40 11.76 12 42663 374 29531478
Drug clearance decreased 25.25 11.76 19 42656 1411 29530441
Haematotoxicity 25.08 11.76 39 42636 6660 29525192
Therapeutic product effect decreased 24.77 11.76 6 42669 29445 29502407
Cytopenia 24.61 11.76 48 42627 9811 29522041
International normalised ratio increased 24.51 11.76 17 42658 44355 29487497
Pseudoporphyria 24.24 11.76 11 42664 312 29531540
Agitation 24.17 11.76 23 42652 51281 29480571
Bone marrow disorder 23.87 11.76 19 42656 1533 29530319
Condition aggravated 23.42 11.76 120 42555 146175 29385677
Aggression 23.37 11.76 11 42664 35530 29496322
Post embolisation syndrome 22.87 11.76 7 42668 62 29531790
Bone neoplasm 22.67 11.76 10 42665 265 29531587
B-cell small lymphocytic lymphoma 22.52 11.76 8 42667 117 29531735
Anaphylactic reaction 22.45 11.76 6 42669 27567 29504285
Bone marrow transplant 22.41 11.76 15 42660 925 29530927
Cardio-respiratory arrest 22.34 11.76 24 42651 50577 29481275
Epistaxis 22.30 11.76 25 42650 51679 29480173
Large intestine infection 22.18 11.76 17 42658 1298 29530554
Philadelphia chromosome negative 22.17 11.76 4 42671 0 29531852
Spleen palpable 22.17 11.76 4 42671 0 29531852
Acute aortic syndrome 22.17 11.76 4 42671 0 29531852
C-kit gene mutation 22.17 11.76 4 42671 0 29531852
Right ventricular diastolic collapse 22.11 11.76 7 42668 70 29531782
Dengue fever 21.91 11.76 9 42666 199 29531653
Urticaria 21.91 11.76 28 42647 54632 29477220
Chronic graft versus host disease in skin 21.73 11.76 14 42661 809 29531043
Dehydration 21.40 11.76 89 42586 114659 29417193
Transformation to acute myeloid leukaemia 21.31 11.76 13 42662 682 29531170
Ocular myasthenia 21.19 11.76 9 42666 217 29531635
Suicidal ideation 20.96 11.76 12 42663 34704 29497148
Chronic obstructive pulmonary disease 20.94 11.76 17 42658 40938 29490914
Intentional product misuse 20.90 11.76 12 42663 34649 29497203
Rectosigmoid cancer 20.74 11.76 8 42667 149 29531703
Pancytopenia 20.72 11.76 197 42478 82971 29448881
Arterial disorder 20.24 11.76 15 42660 1088 29530764
Anaemia 20.11 11.76 404 42271 200547 29331305
Concomitant disease aggravated 20.07 11.76 30 42645 4948 29526904
Complications of transplant surgery 20.03 11.76 11 42664 473 29531379
Myelocyte count increased 20.02 11.76 10 42665 353 29531499
Pericardial excision 19.94 11.76 4 42671 3 29531849
Encephalopathy 19.81 11.76 10 42665 31033 29500819
Mental status changes 19.80 11.76 13 42662 34914 29496938
Bone marrow oedema 19.75 11.76 11 42664 486 29531366
Neuropathy peripheral 19.68 11.76 46 42629 70981 29460871
Graft versus host disease in lung 19.67 11.76 11 42664 490 29531362
Peripheral arterial occlusive disease 19.63 11.76 30 42645 5046 29526806
Neoplasm 19.60 11.76 27 42648 4134 29527718
Diaphragmatic disorder 19.49 11.76 14 42661 968 29530884
Pigmentation disorder 19.39 11.76 19 42656 2020 29529832
Atrial fibrillation 19.04 11.76 83 42592 105563 29426289
Intentional product use issue 18.94 11.76 20 42655 42478 29489374
Suicide attempt 18.93 11.76 13 42662 34097 29497755
Colitis 18.59 11.76 11 42664 31237 29500615
Renal-limited thrombotic microangiopathy 18.51 11.76 4 42671 6 29531846
Medication error 18.48 11.76 4 42671 21207 29510645
Vomiting 18.42 11.76 418 42257 211842 29320010
Psoriasis 18.26 11.76 12 42663 32215 29499637
Dropped head syndrome 18.12 11.76 7 42668 131 29531721
Wheezing 18.01 11.76 13 42662 33227 29498625
Leukostasis syndrome 17.89 11.76 5 42670 31 29531821
Leukocytosis 17.84 11.76 69 42606 21073 29510779
Hyponatraemia 17.79 11.76 45 42630 67588 29464264
Abscess drainage 17.66 11.76 8 42667 226 29531626
Hepatic calcification 17.58 11.76 9 42666 335 29531517
Lactic acidosis 17.50 11.76 11 42664 30236 29501616
Acoustic neuroma 17.42 11.76 7 42668 146 29531706
Chest expansion decreased 17.33 11.76 7 42668 148 29531704
Adrenomegaly 17.26 11.76 9 42666 348 29531504
Therapy change 17.24 11.76 20 42655 2578 29529274
Periorbital swelling 17.19 11.76 9 42666 351 29531501
Marrow hyperplasia 17.13 11.76 13 42662 978 29530874
Costal cartilage fracture 17.06 11.76 8 42667 245 29531607
Tachycardia 16.94 11.76 51 42624 72359 29459493
Gelatinous transformation of the bone marrow 16.90 11.76 4 42671 11 29531841
Acinetobacter sepsis 16.90 11.76 5 42670 39 29531813
Stress 16.89 11.76 5 42670 21485 29510367
Gastrointestinal toxicity 16.89 11.76 18 42657 2113 29529739
Leukaemia 16.87 11.76 24 42651 3786 29528066
Leukaemic infiltration 16.69 11.76 6 42669 91 29531761
Essential thrombocythaemia 16.68 11.76 5 42670 41 29531811
Hydrocele operation 16.63 11.76 3 42672 0 29531852
Pseudomyxoma peritonei 16.63 11.76 3 42672 0 29531852
Hepatic embolisation 16.63 11.76 3 42672 0 29531852
Cytoreductive surgery 16.63 11.76 3 42672 0 29531852
Product dose omission issue 16.60 11.76 77 42598 96306 29435546
Blood pressure decreased 16.52 11.76 25 42650 45452 29486400
Multiple-drug resistance 16.44 11.76 24 42651 3876 29527976
Intestinal congestion 16.40 11.76 4 42671 13 29531839
Paternal exposure during pregnancy 16.40 11.76 4 42671 13 29531839
Thrombosis 16.28 11.76 23 42652 43022 29488830
Platelet count increased 16.23 11.76 37 42638 8426 29523426
Biopsy bone marrow abnormal 16.18 11.76 8 42667 276 29531576
Cellulitis 15.89 11.76 26 42649 45814 29486038
Retroperitoneal fibrosis 15.87 11.76 8 42667 288 29531564
Metastases to bladder 15.45 11.76 5 42670 54 29531798
Constipation 15.37 11.76 99 42576 114061 29417791
Growth failure 15.21 11.76 5 42670 57 29531795
Oropharyngeal pain 15.16 11.76 12 42663 29273 29502579
Lactose intolerance 15.12 11.76 13 42662 1168 29530684
Hyperkeratosis 15.08 11.76 21 42654 3248 29528604
Loss of personal independence in daily activities 15.07 11.76 9 42666 25431 29506421
Foetal exposure during pregnancy 15.02 11.76 16 42659 33851 29498001
Trisomy 8 14.90 11.76 5 42670 61 29531791
Lung neoplasm malignant 14.78 11.76 50 42625 14307 29517545
Parakeratosis 14.76 11.76 6 42669 129 29531723
Metastases to heart 14.59 11.76 6 42669 133 29531719
Drug dependence 14.57 11.76 6 42669 20975 29510877
Bence Jones proteinuria 14.55 11.76 3 42672 3 29531849
Breast oedema 14.55 11.76 3 42672 3 29531849
Pneumonia aspiration 14.53 11.76 19 42656 36718 29495134
Myalgia 14.49 11.76 167 42508 73852 29458000
Heart rate decreased 14.49 11.76 9 42666 24903 29506949
Product prescribing error 14.47 11.76 4 42671 17972 29513880
Musculoskeletal stiffness 14.18 11.76 20 42655 37438 29494414
Presyncope 14.08 11.76 3 42672 16086 29515766
Blood creatinine increased 14.07 11.76 186 42489 84916 29446936
Coma 14.02 11.76 22 42653 39428 29492424
Lacrimation increased 13.93 11.76 31 42644 6949 29524903
Skin depigmentation 13.70 11.76 8 42667 387 29531465
Chills 13.47 11.76 55 42620 71245 29460607
Bladder neoplasm surgery 13.43 11.76 4 42671 32 29531820
Unresponsive to stimuli 13.38 11.76 10 42665 25116 29506736
Lipase increased 13.36 11.76 34 42641 8303 29523549
Unevaluable event 13.35 11.76 14 42661 29837 29502015
Clear cell sarcoma of soft tissue 13.34 11.76 3 42672 6 29531846
Janus kinase 2 mutation 13.34 11.76 3 42672 6 29531846
Fibrin D dimer decreased 13.34 11.76 3 42672 6 29531846
Aspiration bone marrow 13.34 11.76 3 42672 6 29531846
Nasopharyngitis 13.26 11.76 43 42632 59622 29472230
Hepatotoxicity 13.23 11.76 56 42619 17811 29514041
Angioedema 13.15 11.76 16 42659 31899 29499953
Therapy responder 13.10 11.76 6 42669 174 29531678
Skin exfoliation 13.09 11.76 66 42609 22579 29509273
Transitional cell carcinoma 13.01 11.76 15 42660 1920 29529932
Polyserositis 12.97 11.76 6 42669 178 29531674
Bladder cancer 12.94 11.76 38 42637 10089 29521763
Metastasis 12.89 11.76 20 42655 3409 29528443
Lymphocytic infiltration 12.87 11.76 9 42666 596 29531256
Cancer surgery 12.84 11.76 8 42667 436 29531416
Abdominal pain 12.81 11.76 270 42405 135087 29396765
Hydrothorax 12.77 11.76 8 42667 440 29531412
Axonal neuropathy 12.59 11.76 10 42665 804 29531048
Ejection fraction decreased 12.55 11.76 51 42624 15927 29515925
Oxygen saturation decreased 12.52 11.76 29 42646 44908 29486944
Ileus paralytic 12.52 11.76 25 42650 5198 29526654
Generalised tonic-clonic seizure 12.46 11.76 6 42669 19133 29512719
Insomnia 12.45 11.76 76 42599 88685 29443167
Bone development abnormal 12.38 11.76 4 42671 43 29531809
Swelling face 12.25 11.76 60 42615 20290 29511562
Hypereosinophilic syndrome 12.25 11.76 6 42669 203 29531649
Dysarthria 12.21 11.76 16 42659 30895 29500957
Conjunctival haemorrhage 12.20 11.76 17 42658 2631 29529221
Orthostatic hypotension 12.06 11.76 9 42666 22620 29509232
Erythropoiesis abnormal 12.03 11.76 6 42669 211 29531641
Blast cell proliferation 12.02 11.76 3 42672 11 29531841
Laryngeal cancer stage III 12.02 11.76 3 42672 11 29531841
Myeloproliferative neoplasm 11.97 11.76 8 42667 492 29531360
Skin neoplasm excision 11.97 11.76 7 42668 340 29531512
Lower limb fracture 11.95 11.76 20 42655 3632 29528220
Asthma 11.91 11.76 19 42656 33830 29498022
Disease recurrence 11.88 11.76 50 42625 15864 29515988
Arterial intramural haematoma 11.83 11.76 4 42671 50 29531802

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Death 2635.10 11.95 2680 56386 480025 63959641
Drug resistance 1185.01 11.95 598 58468 34504 64405162
Blast crisis in myelogenous leukaemia 926.33 11.95 201 58865 608 64439058
Second primary malignancy 755.40 11.95 318 58748 12019 64427647
Malignant neoplasm progression 724.31 11.95 689 58377 112182 64327484
Cytogenetic analysis abnormal 639.29 11.95 154 58912 827 64438839
Philadelphia chromosome positive 502.32 11.95 116 58950 501 64439165
Periorbital oedema 355.72 11.95 161 58905 7253 64432413
Chromosome analysis abnormal 344.37 11.95 71 58995 153 64439513
Acute lymphocytic leukaemia recurrent 319.25 11.95 125 58941 3901 64435765
Pleural effusion 304.97 11.95 470 58596 126089 64313577
Neoplasm malignant 265.45 11.95 203 58863 24485 64415181
Leukaemia recurrent 246.85 11.95 92 58974 2502 64437164
Oedema 246.47 11.95 359 58707 91576 64348090
Gene mutation identification test positive 242.09 11.95 53 59013 169 64439497
Chronic myeloid leukaemia recurrent 239.38 11.95 55 59011 231 64439435
Gene mutation 232.16 11.95 83 58983 1999 64437667
Chronic myeloid leukaemia transformation 221.18 11.95 50 59016 192 64439474
Muscle spasms 181.98 11.95 400 58666 140623 64299043
Product substitution issue 172.78 11.95 138 58928 17723 64421943
Completed suicide 162.63 11.95 11 59055 224403 64215263
Eyelid oedema 154.48 11.95 111 58955 12168 64427498
Therapeutic response decreased 151.84 11.95 212 58854 51976 64387690
Metastases to liver 147.21 11.95 143 58923 23798 64415868
Cytogenetic abnormality 132.73 11.95 46 59020 1008 64438658
Thrombocytopenia 130.68 11.95 476 58590 223325 64216341
Rheumatoid arthritis 128.61 11.95 5 59061 164289 64275377
Face oedema 125.07 11.95 133 58933 24628 64415038
Disease progression 123.52 11.95 346 58720 141334 64298332
Chronic myeloid leukaemia 121.09 11.95 60 59006 3314 64436352
Bone marrow failure 120.84 11.95 182 58884 47770 64391896
Blast cell crisis 116.09 11.95 27 59039 121 64439545
Fall 114.41 11.95 128 58938 416698 64022968
Chronic graft versus host disease 113.27 11.95 71 58995 6205 64433461
Recurrent cancer 112.13 11.95 51 59015 2322 64437344
Polymerase chain reaction positive 111.88 11.95 30 59036 262 64439404
Splenomegaly 111.77 11.95 108 58958 17853 64421813
Hypotension 110.10 11.95 112 58954 380862 64058804
Gastric antral vascular ectasia 108.50 11.95 37 59029 771 64438895
Growth retardation 104.81 11.95 43 59023 1518 64438148
Drug abuse 103.70 11.95 4 59062 132370 64307296
Fluid retention 102.97 11.95 191 58875 59415 64380251
Eye swelling 99.18 11.95 112 58954 22169 64417497
Drug hypersensitivity 94.45 11.95 50 59016 237765 64201901
Blast cells present 91.59 11.95 33 59033 813 64438853
Nausea 90.68 11.95 1107 57959 784693 63654973
Neoplasm recurrence 90.19 11.95 51 59015 3688 64435978
Injection site pain 88.53 11.95 3 59063 111405 64328261
Myelofibrosis 87.72 11.95 42 59024 2151 64437515
Pancytopenia 87.11 11.95 309 58757 143000 64296666
White blood cell count increased 87.03 11.95 189 58877 65825 64373841
Anaemia 85.90 11.95 617 58449 378063 64061603
Therapy non-responder 84.98 11.95 187 58879 65712 64373954
Oedema peripheral 84.57 11.95 399 58667 209918 64229748
Overdose 84.52 11.95 21 59045 159545 64280121
Generalised oedema 83.07 11.95 99 58967 20754 64418912
Graft versus host disease 82.09 11.95 81 58985 13732 64425934
Hepatotoxicity 81.85 11.95 138 58928 39824 64399842
Metastases to peritoneum 81.85 11.95 47 59019 3500 64436166
Gastrointestinal stromal tumour 81.77 11.95 35 59031 1376 64438290
Blast cell count increased 81.70 11.95 34 59032 1245 64438421
Pseudoporphyria 81.40 11.95 27 59039 515 64439151
Acquired gene mutation 79.33 11.95 38 59028 1948 64437718
Drug intolerance 76.55 11.95 358 58708 187634 64252032
Haematotoxicity 75.49 11.95 75 58991 12821 64426845
Bone pain 74.22 11.95 146 58920 47426 64392240
Rash 74.22 11.95 692 58374 457857 63981809
Arthropathy 72.19 11.95 12 59054 120955 64318711
Platelet count decreased 70.95 11.95 323 58743 167388 64272278
Confusional state 70.67 11.95 81 58985 261063 64178603
Pericardial effusion 70.58 11.95 128 58938 39126 64400540
Central nervous system leukaemia 69.30 11.95 22 59044 363 64439303
Pain 69.22 11.95 267 58799 553244 63886422
Haemoglobin decreased 69.09 11.95 357 58709 194706 64244960
Thrombocytosis 68.58 11.95 55 59011 7101 64432565
Neoplasm progression 67.91 11.95 129 58937 40835 64398831
Therapeutic product effect decreased 65.47 11.95 13 59053 115338 64324328
Desmoid tumour 64.72 11.95 17 59049 136 64439530
Neutropenia 64.16 11.95 407 58659 239217 64200449
Necrotising panniculitis 62.29 11.95 14 59052 52 64439614
Conjunctival haemorrhage 59.99 11.95 44 59022 4977 64434689
Therapy partial responder 58.87 11.95 59 59007 10189 64429477
Clonal evolution 58.01 11.95 17 59049 211 64439455
Intentional overdose 55.76 11.95 8 59058 89936 64349730
Stem cell transplant 54.47 11.95 36 59030 3445 64436221
Tumour necrosis 54.33 11.95 28 59038 1681 64437985
Loss of therapeutic response 54.15 11.95 17 59049 270 64439396
Normal newborn 53.46 11.95 43 59023 5574 64434092
Blood lactate dehydrogenase increased 53.39 11.95 103 58963 32975 64406691
Injection site erythema 52.65 11.95 3 59063 70797 64368869
Acute kidney injury 52.14 11.95 223 58843 449017 63990649
Sinusitis 51.83 11.95 35 59031 145893 64293773
Leukocytosis 50.81 11.95 109 58957 37631 64402035
Bone marrow transplant 49.51 11.95 24 59042 1263 64438403
Urinary tract infection 49.51 11.95 85 58981 231511 64208155
Ascites 48.74 11.95 146 58920 61855 64377811
Blood pressure increased 48.32 11.95 52 59014 172500 64267166
Toxicity to various agents 48.20 11.95 171 58895 363342 64076324
Swelling face 47.15 11.95 140 58926 59026 64380640
Gastrointestinal toxicity 46.99 11.95 39 59027 5283 64434383
Condition aggravated 46.89 11.95 179 58887 372247 64067419
Bone marrow necrosis 46.83 11.95 14 59052 187 64439479
Product use issue 46.77 11.95 42 59024 151673 64287993
Central nervous system neoplasm 46.60 11.95 12 59054 88 64439578
Tumour excision 45.17 11.95 17 59049 475 64439191
Surgery 44.50 11.95 87 58979 28126 64411540
Diarrhoea 44.09 11.95 916 58150 721788 63717878
Bradycardia 43.82 11.95 27 59039 118192 64321474
Off label use 42.97 11.95 372 58694 632434 63807232
Bone marrow oedema 42.90 11.95 21 59045 1129 64438537
Prostate cancer 42.72 11.95 70 58996 19725 64419941
Tumour rupture 42.56 11.95 15 59051 346 64439320
Endocarditis noninfective 42.47 11.95 13 59053 189 64439477
Treatment failure 41.45 11.95 214 58852 116602 64323064
Nasopharyngitis 40.95 11.95 73 58993 196000 64243666
Tumour haemorrhage 40.36 11.95 30 59036 3463 64436203
Dizziness 39.86 11.95 231 58835 429932 64009734
Somnolence 39.73 11.95 79 58987 203566 64236100
Peripheral arterial occlusive disease 39.72 11.95 40 59026 6947 64432719
Vomiting 39.48 11.95 716 58350 550401 63889265
Cytopenia 39.35 11.95 59 59007 15412 64424254
Chloroma 39.25 11.95 17 59049 688 64438978
Joint swelling 39.13 11.95 87 58979 215295 64224371
Inappropriate schedule of product administration 38.71 11.95 18 59048 92268 64347398
Flushing 38.55 11.95 12 59054 78636 64361030
White blood cell count decreased 38.49 11.95 262 58804 157575 64282091
Oral pigmentation 38.26 11.95 8 59058 19 64439647
Musculoskeletal stiffness 38.10 11.95 34 59032 123172 64316494
Arthritis 37.30 11.95 15 59051 83799 64355867
Anaphylactic reaction 36.41 11.95 9 59057 68655 64371011
Asthma 36.34 11.95 21 59045 95204 64344462
Hyperkalaemia 36.24 11.95 24 59042 101105 64338561
Pulmonary aplasia 35.98 11.95 6 59060 0 64439666
Erythrocyanosis 35.98 11.95 6 59060 0 64439666
Loss of personal independence in daily activities 35.61 11.95 11 59055 72443 64367223
Pubertal failure 35.00 11.95 7 59059 12 64439654
Post embolisation syndrome 34.83 11.95 9 59057 67 64439599
Suicidal ideation 34.75 11.95 9 59057 66533 64373133
Lower respiratory tract infection 34.52 11.95 22 59044 94592 64345074
Syncope 34.46 11.95 57 59009 157578 64282088
Urticaria 34.36 11.95 51 59015 147266 64292400
Anxiety 34.30 11.95 85 58981 202564 64237102
Skin fragility 34.11 11.95 16 59050 782 64438884
Trisomy 8 33.98 11.95 7 59059 15 64439651
Drug clearance decreased 33.68 11.95 24 59042 2595 64437071
Discomfort 33.58 11.95 16 59050 80862 64358804
Myalgia 33.30 11.95 254 58812 158363 64281303
Delirium 33.13 11.95 11 59055 69183 64370483
Carotid intima-media thickness increased 33.03 11.95 9 59057 84 64439582
Colon cancer 33 11.95 49 59017 12690 64426976
Gastric cancer 33.00 11.95 35 59031 6458 64433208
Aplasia 32.74 11.95 36 59030 6917 64432749
Therapeutic response delayed 32.59 11.95 16 59050 866 64438800
Cardiac output decreased 32.58 11.95 20 59046 1684 64437982
Hallucination 32.43 11.95 13 59053 72775 64366891
Pyrexia 32.02 11.95 702 58364 557942 63881724
Hypersensitivity 32.01 11.95 84 58982 196368 64243298
Eye oedema 31.85 11.95 20 59046 1753 64437913
Therapy change 31.49 11.95 34 59032 6400 64433266
Pituitary apoplexy 31.39 11.95 10 59056 167 64439499
Tremor 31.11 11.95 55 59011 148175 64291491
Chronic graft versus host disease in skin 30.95 11.95 18 59048 1373 64438293
Eye haemorrhage 30.54 11.95 38 59028 8322 64431344
Hyperhidrosis 30.36 11.95 42 59024 124878 64314788
Papilloedema 30.35 11.95 31 59035 5474 64434192
Pulmonary embolism 30.09 11.95 55 59011 146301 64293365
Slit-lamp tests abnormal 29.98 11.95 5 59061 0 64439666
Graft versus host disease in eye 29.69 11.95 11 59055 294 64439372
Suicide attempt 29.55 11.95 14 59052 70993 64368673
Ankle brachial index decreased 29.52 11.95 8 59058 73 64439593
Metabolic acidosis 29.51 11.95 14 59052 70944 64368722
Metastasis 29.48 11.95 31 59035 5664 64434002
Pulse waveform abnormal 29.33 11.95 8 59058 75 64439591
Blood pressure fluctuation 29.10 11.95 6 59060 51865 64387801
Arterial disorder 29.05 11.95 19 59047 1786 64437880
Exposure via father 29.05 11.95 8 59058 78 64439588
Agitation 29.02 11.95 23 59043 88344 64351322
Wound 28.99 11.95 17 59049 76460 64363206
Right ventricular diastolic collapse 28.86 11.95 8 59058 80 64439586
Cardiotoxicity 28.77 11.95 41 59025 10233 64429433
Jaw operation 28.74 11.95 14 59052 745 64438921
Rhabdomyolysis 28.73 11.95 25 59041 91701 64347965
Leukaemia 28.69 11.95 29 59037 5059 64434607
Mobility decreased 28.62 11.95 22 59044 85818 64353848
Acute lymphocytic leukaemia 28.55 11.95 27 59039 4344 64435322
Pneumonia 28.47 11.95 352 58714 559224 63880442
Cardio-respiratory arrest 28.26 11.95 29 59037 98364 64341302
Glossodynia 28.10 11.95 12 59054 64684 64374982
Deep vein thrombosis 28.01 11.95 33 59033 105149 64334517
Product use in unapproved indication 27.67 11.95 265 58801 176353 64263313
Platelet count increased 27.50 11.95 56 59010 18640 64421026
Toxic skin eruption 27.46 11.95 57 59009 19227 64420439
Lactic acidosis 27.31 11.95 11 59055 61399 64378267
Psoriasis 27.09 11.95 16 59050 71687 64367979
Skin hypopigmentation 26.91 11.95 14 59052 857 64438809
Back pain 26.67 11.95 128 58938 250043 64189623
Injury 26.63 11.95 9 59057 55983 64383683
Cardiac arrest 26.55 11.95 64 59002 154000 64285666
Eosinophilia 26.53 11.95 86 58980 37990 64401676
Loss of CAR T-cell persistence 26.35 11.95 6 59060 24 64439642
Scleroderma 26.33 11.95 27 59039 4791 64434875
Lacrimation increased 25.86 11.95 54 59012 18292 64421374
Liver disorder 25.77 11.95 107 58959 53244 64386422
Chylothorax 25.56 11.95 12 59054 588 64439078
Chronic obstructive pulmonary disease 25.27 11.95 17 59049 71031 64368635
Hyponatraemia 25.26 11.95 62 59004 148277 64291389
Disseminated intravascular coagulation 25.25 11.95 76 58990 32272 64407394
Headache 25.09 11.95 338 58728 529129 63910537
Acute graft versus host disease 25.07 11.95 36 59030 9048 64430618
Metamyelocyte count increased 25.02 11.95 12 59054 617 64439049
Growth failure 25.01 11.95 9 59057 221 64439445
Sedation 24.98 11.95 4 59062 41458 64398208
Hypertension 24.63 11.95 138 58928 259123 64180543
Parakeratosis 24.59 11.95 10 59056 345 64439321
Multiple-drug resistance 24.47 11.95 30 59036 6472 64433194
Platelet dysfunction 24.32 11.95 10 59056 355 64439311
International normalised ratio increased 24.29 11.95 22 59044 79145 64360521
Heart rate decreased 24.26 11.95 10 59056 55057 64384609
Oxygen saturation decreased 24.12 11.95 38 59028 107138 64332528
Janus kinase 2 mutation 23.99 11.95 4 59062 0 64439666
Acute aortic syndrome 23.99 11.95 4 59062 0 64439666
Philadelphia chromosome negative 23.99 11.95 4 59062 0 64439666
Blood creatinine increased 23.93 11.95 209 58857 135573 64304093
Seizure 23.79 11.95 76 58990 166816 64272850
Marrow hyperplasia 23.34 11.95 15 59051 1369 64438297
Therapy cessation 23.19 11.95 74 58992 32415 64407251
Transdifferentiation of neoplasm 23.18 11.95 7 59059 97 64439569
Cancer surgery 23.06 11.95 12 59054 735 64438931
Hepatomegaly 22.99 11.95 49 59017 16833 64422833
Blood bilirubin increased 22.94 11.95 109 58957 57444 64382222
Pericardial excision 22.84 11.95 6 59060 48 64439618
Acute myeloid leukaemia 22.84 11.95 66 59000 27397 64412269
Pneumatosis intestinalis 22.78 11.95 26 59040 5203 64434463
Bladder cancer 22.60 11.95 38 59028 10936 64428730
Helicobacter infection 22.45 11.95 4 59062 38358 64401308
Skin exfoliation 22.45 11.95 91 58975 44794 64394872
Insomnia 22.40 11.95 99 58967 197737 64241929
Medication error 22.13 11.95 9 59057 49957 64389709
Presyncope 22.03 11.95 3 59063 35086 64404580
Disease recurrence 21.80 11.95 71 58995 31439 64408227
Gastrectomy 21.73 11.95 10 59056 468 64439198
Acute myeloid leukaemia recurrent 21.71 11.95 19 59047 2765 64436901
Duodenal ulcer perforation 21.64 11.95 3 59063 34622 64405044
Sleep disorder 21.62 11.95 14 59052 59695 64379971
Generalised tonic-clonic seizure 21.57 11.95 5 59061 39852 64399814
Bone marrow disorder 21.47 11.95 19 59047 2806 64436860
Urine odour abnormal 21.47 11.95 25 59041 5111 64434555
Periorbital swelling 21.42 11.95 16 59050 1860 64437806
Orthostatic hypotension 21.40 11.95 8 59058 46730 64392936
Swelling of eyelid 21.33 11.95 17 59049 2175 64437491
Metastases to heart 21.31 11.95 8 59058 222 64439444
Cellulitis 21.27 11.95 33 59033 93624 64346042
Ileus paralytic 21.27 11.95 32 59034 8383 64431283
Ill-defined disorder 21.09 11.95 7 59059 44045 64395621
Neoplasm 21.09 11.95 29 59037 7002 64432664
Mucosal inflammation 21.05 11.95 113 58953 62471 64377195
Hepatic calcification 21.00 11.95 9 59057 355 64439311
Unresponsive to stimuli 20.87 11.95 10 59056 50383 64389283
Impaired healing 20.80 11.95 15 59051 60458 64379208
Ocular myasthenia 20.72 11.95 9 59057 367 64439299
Hepatosplenomegaly 20.67 11.95 25 59041 5318 64434348
Adrenomegaly 20.65 11.95 9 59057 370 64439296
Large intestine infection 20.63 11.95 18 59048 2610 64437056
Skin depigmentation 20.62 11.95 12 59054 916 64438750
Blood alkaline phosphatase increased 20.58 11.95 104 58962 56175 64383491
Costal cartilage fracture 20.51 11.95 8 59058 247 64439419
Delayed puberty 20.47 11.95 7 59059 147 64439519
Aspiration pleural cavity 20.44 11.95 14 59052 1421 64438245
Lichen planus 20.43 11.95 17 59049 2311 64437355
Lactose intolerance 20.40 11.95 16 59050 2000 64437666
Malaise 20.21 11.95 249 58817 395998 64043668
Myelocyte count increased 20.17 11.95 11 59055 741 64438925
Osteoarthritis 20.15 11.95 17 59049 63319 64376347
Ejection fraction decreased 20.14 11.95 65 59001 28642 64411024
Intentional product misuse 19.98 11.95 22 59044 72273 64367393
Pseudomyxoma peritonei 19.95 11.95 4 59062 7 64439659
Haemorrhagic ascites 19.92 11.95 8 59058 267 64439399
Myelodysplastic syndrome 19.86 11.95 63 59003 27516 64412150
Basophilia 19.74 11.95 5 59061 34 64439632
Wheezing 19.66 11.95 27 59039 80552 64359114
Balance disorder 19.61 11.95 29 59037 83897 64355769
Stress 19.57 11.95 16 59050 60518 64379148
Left ventricular dysfunction 19.50 11.95 46 59020 16908 64422758
Blindness 19.37 11.95 54 59012 21965 64417701
Therapy responder 19.34 11.95 9 59057 432 64439234
Renal tuberculosis 19.03 11.95 5 59061 40 64439626
Intestinal congestion 18.99 11.95 4 59062 10 64439656
Chest expansion decreased 18.86 11.95 7 59059 188 64439478
Red blood cell count decreased 18.82 11.95 91 58975 48295 64391371
Lichenoid keratosis 18.79 11.95 19 59047 3315 64436351
Blood blister 18.76 11.95 17 59049 2591 64437075
Mental status changes 18.75 11.95 17 59049 61145 64378521
Demyelination 18.73 11.95 27 59039 6807 64432859
Blood pressure systolic increased 18.73 11.95 11 59055 49442 64390224
Intentional product use issue 18.58 11.95 37 59029 95327 64344339
Spleen palpable 18.45 11.95 4 59062 12 64439654
Obliterative bronchiolitis 18.44 11.95 17 59049 2648 64437018
Epistaxis 18.33 11.95 39 59027 98092 64341574
Loss of consciousness 18.18 11.95 72 58994 148293 64291373
Diaphragmatic disorder 18.17 11.95 13 59053 1415 64438251
Chronic lymphocytic leukaemia 18.03 11.95 21 59045 4294 64435372
Rhinorrhoea 18.00 11.95 17 59049 59952 64379714
Mucosal pigmentation 17.99 11.95 3 59063 0 64439666
Fibrin D dimer decreased 17.99 11.95 3 59063 0 64439666
Skin toxicity 17.98 11.95 26 59040 6576 64433090
Optic neuritis 17.92 11.95 29 59037 8087 64431579
Diabetic ketoacidosis 17.71 11.95 3 59063 29842 64409824
Polymerase chain reaction 17.59 11.95 6 59060 125 64439541
Breast oedema 17.56 11.95 4 59062 16 64439650
Acinetobacter sepsis 17.53 11.95 5 59061 56 64439610
Intra-abdominal haemorrhage 17.49 11.95 20 59046 4011 64435655
Tumour lysis syndrome 17.42 11.95 48 59018 19392 64420274
Philadelphia positive chronic myeloid leukaemia 17.33 11.95 6 59060 131 64439535
Right ventricular failure 17.28 11.95 51 59015 21420 64418246
Renal-limited thrombotic microangiopathy 17.18 11.95 4 59062 18 64439648
Retroperitoneal fibrosis 17.08 11.95 9 59057 566 64439100
Tyrosine kinase mutation 17.01 11.95 4 59062 19 64439647
Interstitial lung disease 16.99 11.95 150 58916 97582 64342084
Pigmentation disorder 16.91 11.95 21 59045 4591 64435075
Aggression 16.52 11.95 11 59055 46221 64393445
Bone metabolism disorder 16.47 11.95 8 59058 423 64439243
Retinal vascular disorder 16.33 11.95 7 59059 276 64439390
Leukaemic infiltration extramedullary 16.31 11.95 6 59060 157 64439509
Coma 16.22 11.95 35 59031 87580 64352086
Computerised tomogram abnormal 16.19 11.95 17 59049 3099 64436567
Feeling hot 16.14 11.95 11 59055 45652 64394014
Anaphylactic shock 16.03 11.95 4 59062 30324 64409342
Blood pressure systolic inspiratory decreased 15.91 11.95 3 59063 3 64439663
Jaundice 15.91 11.95 87 58979 48425 64391241
Oesophagectomy 15.91 11.95 3 59063 3 64439663
Myeloproliferative neoplasm 15.90 11.95 10 59056 879 64438787
Leukopenia 15.89 11.95 152 58914 101090 64338576
Vaccination failure 15.88 11.95 10 59056 881 64438785
Product dose omission issue 15.72 11.95 109 58957 194638 64245028
Blood fibrinogen decreased 15.69 11.95 12 59054 1446 64438220
Polyserositis 15.62 11.95 8 59058 474 64439192
Nasal congestion 15.58 11.95 19 59047 59639 64380027
Bone marrow leukaemic cell infiltration 15.45 11.95 4 59062 30 64439636
Bone neoplasm 15.42 11.95 9 59057 691 64438975
Paraesthesia 15.41 11.95 67 58999 134455 64305211
Knee arthroplasty 15.40 11.95 3 59063 26996 64412670
Karyotype analysis abnormal 15.34 11.95 4 59062 31 64439635
Haematocrit decreased 15.31 11.95 94 58972 54561 64385105
Lung infiltration 15.30 11.95 48 59018 20841 64418825
Intracardiac mass 15.09 11.95 5 59061 95 64439571
Intentional self-injury 15.02 11.95 4 59062 29040 64410626
Allogenic bone marrow transplantation therapy 15.01 11.95 4 59062 34 64439632
Hydrothorax 14.98 11.95 11 59055 1246 64438420
Accidental exposure to product 14.89 11.95 3 59063 26361 64413305
C-kit gene mutation 14.70 11.95 3 59063 6 64439660
Atrial fibrillation 14.69 11.95 94 58972 170995 64268671
Wrong technique in product usage process 14.65 11.95 23 59043 64951 64374715
Irritable bowel syndrome 14.60 11.95 8 59058 37361 64402305
Stenotrophomonas infection 14.59 11.95 16 59050 3064 64436602
B-cell small lymphocytic lymphoma 14.58 11.95 5 59061 106 64439560
Dysarthria 14.40 11.95 20 59046 59386 64380280
Oropharyngeal cancer 14.28 11.95 5 59061 113 64439553
Graft versus host disease in lung 14.27 11.95 9 59057 795 64438871
Bone development abnormal 14.17 11.95 4 59062 43 64439623
Pemphigus 14.16 11.95 21 59045 60680 64378986
Thrombosis 14.11 11.95 27 59039 70615 64369051
Psychotic disorder 14.11 11.95 7 59059 34571 64405095
Blood cholesterol increased 14.10 11.95 15 59051 50051 64389615
Typhoid fever 14.09 11.95 4 59062 44 64439622
Concomitant disease aggravated 14.02 11.95 32 59034 11510 64428156
Folliculitis 14.02 11.95 5 59061 30072 64409594
Heart rate increased 14.01 11.95 45 59021 98630 64341036
Tachycardia 13.98 11.95 80 58986 149499 64290167
Dropped head syndrome 13.94 11.95 6 59060 239 64439427
Myelocytosis 13.93 11.95 4 59062 46 64439620
Blood pressure decreased 13.92 11.95 37 59029 86162 64353504
Skin hyperpigmentation 13.91 11.95 23 59043 6528 64433138
Myoclonus 13.90 11.95 3 59063 25115 64414551
Feeling abnormal 13.85 11.95 69 58997 133533 64306133
Concomitant disease progression 13.81 11.95 16 59050 3253 64436413
Influenza like illness 13.76 11.95 22 59044 61680 64377986
Therapy interrupted 13.73 11.95 45 59021 19991 64419675
Type 2 diabetes mellitus 13.71 11.95 7 59059 34013 64405653
Emotional distress 13.67 11.95 8 59058 36030 64403636
Subdural haematoma evacuation 13.55 11.95 4 59062 51 64439615
Contusion 13.52 11.95 56 59010 113909 64325757
Skin neoplasm excision 13.47 11.95 9 59057 877 64438789
Biopsy bone marrow abnormal 13.45 11.95 7 59059 429 64439237
Clear cell sarcoma of soft tissue 13.38 11.95 3 59063 11 64439655
Polyhydramnios 13.34 11.95 11 59055 1476 64438190
Arthralgia 13.31 11.95 306 58760 441954 63997712
Leukaemic infiltration 13.24 11.95 5 59061 141 64439525
Rash erythematous 13.22 11.95 83 58983 48550 64391116
Azoospermia 13.14 11.95 5 59061 144 64439522
Speech disorder 13.10 11.95 15 59051 48426 64391240
Transitional cell carcinoma 13.01 11.95 13 59053 2236 64437430
Cystitis 12.92 11.95 12 59054 42663 64397003
Cognitive disorder 12.90 11.95 19 59047 55068 64384598
Tumour compression 12.83 11.95 5 59061 154 64439512
Splenectomy 12.80 11.95 8 59058 695 64438971
Oligoasthenozoospermia 12.80 11.95 3 59063 14 64439652
Pancreatic toxicity 12.80 11.95 3 59063 14 64439652
Irritability 12.79 11.95 9 59057 36737 64402929
Essential thrombocythaemia 12.77 11.95 5 59061 156 64439510
Gastric neoplasm 12.74 11.95 6 59060 296 64439370
Pyoderma gangrenosum 12.74 11.95 15 59051 3103 64436563
Depression 12.71 11.95 107 58959 183184 64256482
Hypereosinophilic syndrome 12.69 11.95 7 59059 482 64439184
Cardiac tamponade 12.66 11.95 25 59041 8139 64431527
Myeloblast count increased 12.63 11.95 3 59063 15 64439651
Histology abnormal 12.54 11.95 6 59060 307 64439359
Tuberculosis 12.49 11.95 33 59033 13005 64426661
Constipation 12.48 11.95 142 58924 229195 64210471
Myelosuppression 12.46 11.95 49 59017 23781 64415885
Haemangioma 12.42 11.95 13 59053 2361 64437305
Pericarditis 12.40 11.95 24 59042 62492 64377174
Histiocytic sarcoma 12.38 11.95 4 59062 70 64439596
Skin lesion 12.35 11.95 66 59000 36416 64403250
Bone formation decreased 12.33 11.95 4 59062 71 64439595
Hyperleukocytosis 12.19 11.95 12 59054 2028 64437638
Axonal neuropathy 12.11 11.95 11 59055 1681 64437985
Autoimmune lymphoproliferative syndrome 12.09 11.95 5 59061 180 64439486
Arterial intramural haematoma 12.07 11.95 4 59062 76 64439590
Hypokalaemia 12.05 11.95 64 59002 121839 64317827
Dyskinesia 12.01 11.95 11 59055 39377 64400289
Bronchitis 11.95 11.95 55 59011 108688 64330978

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EA01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
BCR-ABL tyrosine kinase inhibitors
FDA MoA N0000020009 Bcr-Abl Tyrosine Kinase Inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
FDA MoA N0000182137 Cytochrome P450 2D6 Inhibitors
FDA MoA N0000182141 Cytochrome P450 3A4 Inhibitors
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:38637 tyrosine kinase inhibitors
CHEBI has role CHEBI:68495 Type I cell-death inducers
CHEBI has role CHEBI:149553 anticoronaviral drug

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Dermatofibrosarcoma protuberans indication 276799004
Systemic mast cell disease indication 397016004 DOID:349
Blastic phase chronic myeloid leukemia indication 413656006
Chronic eosinophilic leukemia indication 413836008
Chronic phase chronic myeloid leukemia indication 413847001
Gastrointestinal stromal tumor indication 420120006 DOID:9253
Idiopathic hypereosinophilic syndrome indication 423294001
Philadelphia chromosome-positive acute lymphoblastic leukemia indication 425688002
Philadelphia Chromosome Positive Chronic Myelocytic Leukemia indication 449108003
Myelodysplastic/myeloproliferative diseases with re-arrangements of the gene for platelet-derived growth factor receptor (PDGFR) indication 738527001
Chronic Myelocytic Leukemia Accelerated Phase indication
Heart valve disorder contraindication 368009 DOID:4079
Cerebral edema contraindication 2032001
Hypophosphatemia contraindication 4996001
Congenital heart disease contraindication 13213009
Hyperbilirubinemia contraindication 14783006 DOID:2741
Pulmonary edema contraindication 19242006 DOID:11396
Hypertensive disorder contraindication 38341003 DOID:10763
Body fluid retention contraindication 43498006
Chronic heart failure contraindication 48447003
Myocarditis contraindication 50920009 DOID:820
Gastrointestinal perforation contraindication 51875005
Hepatic failure contraindication 59927004
Diabetes mellitus contraindication 73211009 DOID:9351
Gastrointestinal hemorrhage contraindication 74474003
Left heart failure contraindication 85232009
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Bleeding contraindication 131148009
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Edema contraindication 267038008
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Pericardial effusion contraindication 373945007 DOID:118
Purpuric disorder contraindication 387778001
Ascites contraindication 389026000
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Obesity contraindication 414916001 DOID:9970
Pleural Effusions contraindication
Chronic Heart Failure Following Myocardial Infarction contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.96 acidic
pKa2 8.49 Basic
pKa3 4.34 Basic
pKa4 3.73 Basic
pKa5 2.2 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Platelet-derived growth factor receptor beta Kinase INHIBITOR Kd 7.85 CHEMBL CHEMBL
Tyrosine-protein kinase ABL1 Kinase INHIBITOR Kd 8.96 CHEMBL CHEMBL
Mast/stem cell growth factor receptor Kit Kinase INHIBITOR Kd 7.89 CHEMBL CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 6.13 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 6.27 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.71 DRUG MATRIX
Carbonic anhydrase 2 Enzyme Ki 7.52 CHEMBL
Multidrug resistance-associated protein 1 Transporter WOMBAT-PK
ATP-binding cassette sub-family G member 2 Transporter IC50 5.47 CHEMBL
Carbonic anhydrase 1 Enzyme Ki 7.50 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 5.34 CHEMBL
Ribosyldihydronicotinamide dehydrogenase [quinone] Enzyme IC50 6.40 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 7.12 CHEMBL
Carbonic anhydrase 12 Enzyme Ki 6.01 CHEMBL
Epidermal growth factor receptor Kinase Kd 5.12 CHEMBL
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 4.69 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 4.77 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 6.96 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase Ki 4.51 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 7.40 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 5.51 CHEMBL
RAF proto-oncogene serine/threonine-protein kinase Kinase Kd 5.77 CHEMBL
Serine/threonine-protein kinase B-raf Kinase Kd 5.48 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase Kd 5.20 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase IC50 4.59 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase Kd 7.96 CHEMBL
Platelet-derived growth factor receptor alpha Kinase Kd 7.51 CHEMBL
Insulin receptor Kinase AGONIST Ki 5 PDSP
Thromboxane-A synthase Enzyme IC50 6.70 DRUG MATRIX
Mitogen-activated protein kinase 8 Kinase Kd 5.49 CHEMBL
Carbonic anhydrase 3 Enzyme Ki 6.28 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 6.41 CHEMBL
Mitogen-activated protein kinase 10 Kinase Kd 5.51 CHEMBL
Tyrosine-protein kinase JAK2 Kinase Ki 5 PDSP
Tyrosine-protein kinase SYK Kinase IC50 5.30 CHEMBL
Ephrin type-A receptor 8 Kinase Kd 5.85 CHEMBL
Tyrosine-protein kinase Lyn Kinase Kd 6.05 CHEMBL
Cytoplasmic tyrosine-protein kinase BMX Kinase Ki 5 PDSP
Carbonic anhydrase 14 Enzyme Ki 6.33 CHEMBL
Fibroblast growth factor receptor 1 Kinase Ki 5 PDSP
Serine/threonine-protein kinase PLK4 Kinase Kd 5.11 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 8.22 CHEMBL
Fibroblast growth factor receptor 2 Kinase Ki 5 PDSP
Serine/threonine-protein kinase 17A Kinase Kd 5.55 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 5.62 CHEMBL
Mitogen-activated protein kinase 14 Kinase IC50 4.86 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 5.82 CHEMBL
Dual specificity protein kinase CLK1 Kinase Kd 5.35 CHEMBL
Dual specificity protein kinase CLK4 Kinase Kd 5.68 CHEMBL
Mitogen-activated protein kinase 9 Kinase Kd 5.28 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 9.15 CHEMBL
Ephrin type-B receptor 4 Kinase Ki 5 PDSP
Lysine--tRNA ligase Enzyme Ki 5.30 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase Kd 5.06 CHEMBL
Mitogen-activated protein kinase kinase kinase MLT Kinase Kd 5.59 CHEMBL
Casein kinase II subunit alpha' Kinase Kd 5.42 CHEMBL
Maternal embryonic leucine zipper kinase Kinase Kd 5.72 CHEMBL
Serine/threonine-protein kinase TNNI3K Kinase Kd 5.37 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 7.82 CHEMBL
Tyrosine-protein kinase Blk Kinase Kd 6.28 CHEMBL
Cyclin-dependent kinase 19 Kinase Kd 5.26 CHEMBL
Homeodomain-interacting protein kinase 4 Kinase Kd 6.02 CHEMBL
Interleukin-1 receptor-associated kinase 1 Kinase Kd 5.92 CHEMBL
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma Kinase Kd 6.42 CHEMBL
Solute carrier family 22 member 2 Transporter IC50 5.38 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 7.40 CHEMBL
Multidrug and toxin extrusion protein 2 Transporter IC50 6.46 CHEMBL
Solute carrier family 22 member 3 Transporter IC50 4.59 CHEMBL
Platelet-derived growth factor receptor Kinase IC50 7.30 CHEMBL
Tyrosine-protein kinase ABL Kinase IC50 7.40 CHEMBL
Bcr/Abl fusion protein Kinase Ki 7.85 CHEMBL
Ephrin type-B receptor 1 Kinase Ki 5 PDSP
ATP-dependent RNA helicase DDX3X Enzyme Kd 6.36 CHEMBL
Cyclin-G-associated kinase Kinase Kd 6 CHEMBL
Multidrug resistance protein 1 Transporter IC50 5.14 CHEMBL
Carbonic anhydrase 13 Enzyme Ki 5.13 CHEMBL
Carbonic anhydrase 15 Enzyme Ki 7.11 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase IC50 5.56 CHEMBL
Tyrosine-protein kinase ABL1 Kinase IC50 7.97 CHEMBL
Platelet-derived growth factor receptor beta Kinase IC50 6.79 CHEMBL

External reference:

IDSource
4021257 VUID
N0000148698 NUI
D01441 KEGG_DRUG
220127-57-1 SECONDARY_CAS_RN
4021257 VANDF
4021258 VANDF
C0939537 UMLSCUI
CHEBI:45783 CHEBI
STI PDB_CHEM_ID
CHEMBL941 ChEMBL_ID
CHEMBL1642 ChEMBL_ID
D000068877 MESH_DESCRIPTOR_UI
DB00619 DRUGBANK_ID
5687 IUPHAR_LIGAND_ID
8031 INN_ID
BKJ8M8G5HI UNII
5291 PUBCHEM_CID
282386 RXNORM
16030 MMSL
238904 MMSL
41395 MMSL
d04758 MMSL
009151 NDDF
009152 NDDF
129558005 SNOMEDCT_US
391634008 SNOMEDCT_US
414460008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0054-0248 TABLET, FILM COATED 100 mg ORAL ANDA 26 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0054-0248 TABLET, FILM COATED 100 mg ORAL ANDA 26 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0054-0249 TABLET, FILM COATED 400 mg ORAL ANDA 26 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0054-0249 TABLET, FILM COATED 400 mg ORAL ANDA 26 sections
Gleevec HUMAN PRESCRIPTION DRUG LABEL 1 0078-0401 TABLET 100 mg ORAL NDA 32 sections
Gleevec HUMAN PRESCRIPTION DRUG LABEL 1 0078-0401 TABLET 100 mg ORAL NDA 32 sections
Gleevec HUMAN PRESCRIPTION DRUG LABEL 1 0078-0649 TABLET 400 mg ORAL NDA 32 sections
Gleevec HUMAN PRESCRIPTION DRUG LABEL 1 0078-0649 TABLET 400 mg ORAL NDA 32 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0093-7629 TABLET, FILM COATED 100 mg ORAL ANDA 28 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0093-7630 TABLET, FILM COATED 400 mg ORAL ANDA 28 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0378-2245 TABLET, FILM COATED 100 mg ORAL ANDA 28 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0378-2245 TABLET, FILM COATED 100 mg ORAL ANDA 28 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0378-2246 TABLET, FILM COATED 400 mg ORAL ANDA 28 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0378-2246 TABLET, FILM COATED 400 mg ORAL ANDA 28 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6621 TABLET, FILM COATED 400 mg ORAL ANDA 26 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6901 TABLET, FILM COATED 100 mg ORAL ANDA 26 sections
imatinib mesylate Human Prescription Drug Label 1 16714-704 TABLET, FILM COATED 100 mg ORAL ANDA 29 sections
imatinib mesylate Human Prescription Drug Label 1 16714-704 TABLET, FILM COATED 100 mg ORAL ANDA 29 sections
imatinib mesylate Human Prescription Drug Label 1 16714-705 TABLET, FILM COATED 400 mg ORAL ANDA 29 sections
imatinib mesylate Human Prescription Drug Label 1 16714-705 TABLET, FILM COATED 400 mg ORAL ANDA 29 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 42292-043 TABLET, FILM COATED 100 mg ORAL ANDA 28 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 42292-044 TABLET, FILM COATED 400 mg ORAL ANDA 28 sections
Imatinib HUMAN PRESCRIPTION DRUG LABEL 1 43598-344 TABLET 100 mg ORAL ANDA 26 sections
Imatinib HUMAN PRESCRIPTION DRUG LABEL 1 43598-345 TABLET 400 mg ORAL ANDA 26 sections
imatinib mesylate Human Prescription Drug Label 1 47335-472 TABLET, FILM COATED 100 mg ORAL ANDA 32 sections
imatinib mesylate Human Prescription Drug Label 1 47335-472 TABLET, FILM COATED 100 mg ORAL ANDA 32 sections
imatinib mesylate Human Prescription Drug Label 1 47335-475 TABLET, FILM COATED 400 mg ORAL ANDA 32 sections
imatinib mesylate Human Prescription Drug Label 1 47335-475 TABLET, FILM COATED 400 mg ORAL ANDA 32 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 50268-426 TABLET, FILM COATED 100 mg ORAL ANDA 26 sections
Imatinib Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 50268-426 TABLET, FILM COATED 100 mg ORAL ANDA 26 sections